Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
  • G01N33/57407—Specifically defined cancers
  • G01N33/57415—Specifically defined cancers of breast
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
  • G01N33/57407—Specifically defined cancers
  • G01N33/57419—Specifically defined cancers of colon
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
  • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/81—Protease inhibitors
  • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
  • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/90—Enzymes; Proenzymes
  • G01N2333/914—Hydrolases (3)
  • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
  • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
  • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
  • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
  • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
  • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
  • G01N2333/96486—Metalloendopeptidases (3.4.24)
  • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
  • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7

Definitions

• the present invention relates to a test to be used to screen large populations for the occurrence of cancer.
• the method is based on the measurement of tissue inhibitor of met- alloproteinases 1 (TIMP-1) in body fluids.
• TIMP-1 tissue inhibitor of met- alloproteinases 1
• the invention permits the early identification of patients having colorectal cancer.
• the method is highly specific, and patients with non- malignant conditions, such as inflammatory bowl diseases, are not detected.
• Measure- ment of another similar inhibitor, TIMP-2 does not demonstrate equivalent clinical value, indicating an additional level of specificity of the invention.
• TIMP-1 tissue inhibitor of metalloproteinases type 1
• body fluids including plasma, serum, stool and urine.
• TIMP-1 con- centrations can be determined either as the total TIMP-1 concentration, the free TIMP-1 concentration, the concentration of complexes between TIMP-1 and MMP ' s and/or ratios and fractions thereof, hereafter referred to as TIMP-1 levels.
• individuals with a high likelihood of having cancer e.g. colon cancer
• individuals with low TIMP-1 levels are unlikely to suffer from cancer, e.g. colon cancer.
• the invention can be used to identify individuals with a high probability of having early stage, non-symptomatic cancer, e.g. colon cancer.
• the identified individuals should be further examined and if cancer is found, the patients should be offered surgery, irradiation, and/or adjuvant anti-neoplastic therapy, thereby increasing the chance of cure of cancer for the individual.
• Colorectal cancer is the fourth most frequent cancer in the Western world, with about 130,000 new cases yearly in the US. Forty to 50% of all colorectal cancer patients will be diagnosed with early stage disease (Dukes ' stage A or B). Most of these patients with early stage colorectal cancer can be cured by surgery alone. Thus, risk of recurrence is closely related to stage of disease at time of primary surgery, with about a 10% relapse rate in Dukes ' stage A and 25-30% in Dukes ' stage B. Patients with Dukes' stage C colorectal cancer have a five-year relapse rate of 70% following surgery and are offered adju- vant chemotherapy. Following relapse, the risk of dying of the disease is significant.
• one way to improve survival is to increase the number of patients being diagnosed with early stage disease. Screening for colorectal cancer has been shown to improve survival, however, current tests suffer from a lack of compliance, from low sensitivity, and from the need for strict dietary restrictions. Thus, the development of new and improved tests for the early detection of colorectal cancer is needed.
• MMP's Matrix metalloproteinases
• MMP's tissue inhibitors of MMP's
• TMP's tissue inhibitors of MMP's
• TIMP-1 enzyme-linked immunoassays for the detection of TIMP-1 (Kodama et al, 1989; Cooksley et al, 1990; Clark et al, 1991) and TIMP-2 (Fujimoto et al, 1993) have been described. These assays have been applied to body fluids, e.g. serum, plasma, am- niotic fluid, cerebrospinal fluid, urine, but the number of samples tested has not been sufficient to establish normal ranges for TIMP levels in healthy individuals (Kodama et al, 1989; Clark et al, 1991). Furthermore, none of these assays has been sufficiently vali- dated for technical performance or for clinical use.
• body fluids e.g. serum, plasma, am- niotic fluid, cerebrospinal fluid, urine
• TIMP-1 protein levels in sera from prostate cancer patients and healthy donors showed a high degree of overlap.
• a separate study of plasma from prostate cancer patients and healthy donors showed no difference in TIMP-1 levels between the two groups (Jung et al, 1997).
• markers for screening large populations for the presence of malignant disease. Such markers should be able to identify individuals with a high probability of early stage cancer. These individuals should be further examined, and if cancer is found, they should subsequently be offered surgery, radiation, or adjuvant anti-neoplastic therapy.
• proteinsases and their receptors and inhibitors seem to play a pivotal role in the basic mechanisms leading to cancer invasion, these molecules may be expressed at a very early time point in the carcinogenic process. As many of these molecules exert their bio- logical action extracellularly, they may be present at elevated levels in body fluids, even in patients with early stage invasive malignant disease. Moreover, since these molecules are involved in the more basic features of malignant progression, e.g. invasion and metastasis, it should be investigated whether which forms of cancer that display an increase in these molecules.
• the present invention relates to a method to aid in the diagnosis of colorectal cancer in a patient, said method comprising determining the amount of total, complexed and/or free TIMP-1 levels and ratios and fractions thereof in body fluids such as blood, serum, plasma, urine, faeces or cerebrospinal fluid.
• An aspect of the present invention relates to a method for determining whether an individual is likely to have cancer, the method comprising determining a first parameter representing the concentration of TIMP-1 in body fluid samples, and indicating the individual as having a high likelihood of having cancer if the parameter is at or beyond a discriminating value and indicating the individual as unlikely of having cancer if the parameter is not at or beyond the discriminating value.
• the parameter representing the concentration of TIMP-1 may be the concentration proper of TIMP-1.
• TIMP-1 exists both in free form and in the form of complexes with metalloproteinases, and it has been found that an important parameter is the total concentration of TIMP-1 , that is, the sum of the TIMP-1 in free form and the TIMP-1 in complex forms.
• the other expressions than the concentration proper can represent the concentration, such as, e.g., the concentration multiplied by a factor, etc. etc., and that such other representations can be used equally well for the purpose of the present invention provided the corresponding adjustments are made.
• the discriminating value is a value which has been determined by measuring the parameter in both a healthy control population and a population with known cancer thereby determining the discriminating value which identifies the cancer population with either a predetermined specificity or a predetermined sensitivity based on an analysis of the relation between the parameter values and the known clinical data of the healthy control population and the cancer patient population, such as it is apparent from the detailed discussion in the examples herein.
• the discriminating value determined in this manner is valid for the same experimental setup in future individual tests.
• Specificity is defined as the proportion of positives (i.e. individuals having a parameter representing the concentration of TIMP-1 in body fluid samples higher than a predefined diagnostic level) that are correctly identified by the described method of the invention.
• Sensitivity is defined as the proportion of negatives (i.e. individuals having a parameter representing the concentration of TIMP-1 in body fluid samples lower than a predefined diagnostic level) that are correctly identified by the described method.
• the invention may be used both for an individual and for an entire population.
• the concentration threshold of total TIMP-1 useful as a discriminating value was found to be in the range of 50-160 microgram/L of total TIMP-1 at a specificity of 90%.
• Other experimental setups and other parameters will result in other values which can be determined in accordance with the teachings herein.
• the method can be applied to an unselected population, but more appropriately to a population already identified as having an increased risk of developing cancer, e.g. individuals with a genetic disposition, individuals who have been exposed to carcinogenic substances, or individuals with cancer-predisposing non-malignant diseases.
• the population selected for the invention could represent individuals with a prior polyp, individuals with Crohn's disease or ulcerative colitis, individuals with one or more family members with colorectal cancer, or individuals with a prior resection of an early colorectal cancer.
• the individual When an individual has been identified as having high TIMP-1 levels in his or her body fluid, the individual should be referred for further examination. If a cancer is found, the patient could be offered surgery, radiation or adjuvant anti-neoplastic therapy aiming at curing the patient of cancer.
• Example 1 describes the preparation and validation of an assay that measures total TIMP-1 with high analytical sensitivity and specificity. It is described that healthy blood donors have a very narrow range of plasma total TIMP-1.
• Example 2 the formatting of a TIMP-1 :MMP-9 ELISA is described.
• the format, execution, and validation of this assay are similar to those for total TIMP-1 , except that a poly- clonal antibody against MMP-9 is used in the capture step. By substituting the MMP-9 antibody with an antibody against another MMP, complexes between TIMP-1 and other MMP ' s can be quantitated.
• Example 3 the formatting of a TIMP-1 assay which exclusively measures free TIMP-1 , is described. This assay utilizes a monoclonal anti-TIMP-1 antibody (MAC 19) which only recognises TIMP-1 in its uncomplexed form. Thus, this assay will measure the amount of free TIMP-1 in a sample.
• the execution and validation of this assay are similar to the as- say for total TIMP-1
• TIMP-1 By subtracting the free TIMP-1 concentration from the total TIMP-1 concentration in a biological sample, the concentration of all complexed forms of TIMP-1 can be determined. It should be emphasized that TIMP-1 can form complexes with many of the MMP's and therefore, subtracting one type of complex from the total amount of TIMP-1 will only provide information on the fraction of TIMP-1 not being complexed to this specific MMP.
• Example 4 it is shown that patients suffering from colorectal cancer have significantly elevated total TIMP-1 levels in their preoperative plasma samples.
• a percentile plot of the total TIMP-1 levels in plasma from all colorectal cancer patients and from healthy blood donors shows that a total TIMP-1 concentration of 119.1 ⁇ g/L is the 90 th centile of the healthy donors. Using this cut-off, 68% of the colorectal cancer patients were identified as having elevated plasma TIMP-1 levels.
• total TIMP-1 measurements in plasma identified 75% of the colon cancer patients (diagnostic sensitivity) with a 90% diagnostic specificity (10% of the healthy blood donors were classified as being high).
• the specificity of a given cancer screening test is based on the efficiency of the test to identify only those patients suffering from cancer while patients suffering from non-malignant diseases should not be identified as false positive subjects.
• IBD inflammatory bowl diseases
• Example 6 the additive effect of the measurement of an additional colorectal cancer marker is described Carcino Embryonic Antigen (CEA) was measured in all cancer patient and healthy blood donor samples Combining CEA and the TIMP-1 levels measured by the assay described in Example 1 , it could be shown that while CEA alone gives 35% sensitivity at a 98% specificity, the sensitivity of the combination of CEA and total TIMP-1 as determined by logistic regression analysis increased to 57%, without sacrificing specificity
• CEA Carcino Embryonic Antigen
• Example 8 the use of the TIMP-1 MMP-9 complex assay as an aid for the diagnosis of colorectal cancer is described
• TIMP-1 is known to exist either as the free molecule or in complex with MMP's, preferentially MMP-9 Measuring total TIMP-1 , complexed TIMP-1 and free TIMP-1 will make it possible to validate each of these species for their potential diagnostic value In addition, it will be possible to calculate ratios or any derived algorithm between the different species which might provide additional diagnostic value
• Example 9 the diagnostic value of the combination of total and free TIMP-1 is described
• the specificity of a given cancer screening test is based on the efficacy of the test to iden- tify only those patients suffering from cancer while patients suffering from non-malignant diseases should not be identified as false positive.
• the test was specific for a specific type of cancer, e.g. colon cancer, instead of being a pan- cancer marker.
• Example 10 total plasma TIMP-1 values in preoperative blood samples from a cohort of 322 patients with primary breast cancer (stage I and II) as compared with total TIMP-1 levels in 108 healthy blood donors are described. It was shown that the breast patients had a median, total TIMP-1 level of 88.3 ⁇ g/L, while the healthy donors had a median plasma concentration of total TIMP-1 of 88.9 ⁇ g/L. The difference between these values is not clinically significant, supporting the specificity of TIMP-1 levels for the diagnosis of colorectal cancer. However, it should be studied whether elevated plasma TIMP-1 levels are found in patients with early stage non-colorectal cancer.
• Example 11 total TIMP-1 levels in patients with metastatic breast cancer are de- scribed.
• total TIMP-1 in plasma from women with metastatic breast cancer had a median value of 236 ⁇ g/L, significantly higher than levels in healthy blood donors. This shows the potential of using plasma TIMP-1 levels for the management of breast cancer patients.
• Example 12 the concentrations of TIMP-2 in preoperative plasma samples from patients with colorectal cancer are described.
• TIMP-2 is another tissue inhibitor of metalloproteinases with a high degree of homology to TIMP-1. Using a specific immunoassay for TIMP-2, concentrations of this inhibitor were determined in plasma samples from colorectal cancer patients and in healthy blood donors. No significant differences in plasma TIMP-2 levels were found between the two populations, supporting the unique value of TIMP-1 as an aid for the early diagnosis of colorectal cancer.
• FIG. 1 Kinetic assay for TIMP-1. Progress curves for the change in absorbance at 405 nm produced by hydrolysis of p-nitrophenyl phosphate by solid-phase bound alkaline phosphatase immunoconjugate. The data shown are generated by 4 individual assay wells treated with 4 different concentrations of purified recombinant TIMP-1 ; 10 ⁇ g/L (V- V), 2.5 ⁇ g/L ( ⁇ - ⁇ ), 0.63 ⁇ g/L ( D - D ) and 0.16 ⁇ g/L (O-O). The lines shown have been fitted by simple linear regression.
• Figure 3 Recovery of signal from standard TIMP-1 added in increasing concentration to assay dilution buffer ( D - D ), a 1:100 dilution of EDTA plasma pool ( ⁇ - ⁇ ), a 1 :100 dilution of citrate plasma pool (V-V) and a 1 :100 dilution of heparin plasma pool (O-O).
• the values shown are the means of triplicates.
• the correlation coefficient for each fitted curve is greater than 0.99.
• Figure 4 Western blotting of immunoabsorbed patient plasma sample.
• Lane 1 standard TIMP-1 ;
• lane 2 eluate of patient citrate plasma sample diluted 1 :10 and immunoabsorbed with sheep polyclonal anti-TIMP-1. Bands of non-reduced standard TIMP-1 and TIMP-1 isolated from plasma sample both appear just below 30 kDa.
• Figure 5a Percentiles plot for the level of TIMP-1 ( ⁇ g/L) measured in citrate plasma (O) and EDTA plasma ( ⁇ ) from the same individual in a set of 100 volunteer blood donors.
• Figure 5b Linear regression plot for the level of TIMP-1 in citrate plasma samples compared with EDTA plasma samples from the same 100 individuals.
• Figure 7 Percentile plot for the levels of TIMP-1 ( ⁇ g/L) measured in 194 citrate plasma samples from volunteer blood donors and stratified by sex into 107 males ( ⁇ ) and 87 females (O).
• Figure 8 Graphical illustration of the TIMP-1 :MMP-9 complex ELISA.
• Figure 9 Graphical illustration of the free TIMP-1 ELISA.
• FIG. 10 A plate was coated with the polyclonal anti-MMP-9 antibody. Different concen- trations of TIMP-1 :MMP-9 complex, free MMP-9, free TIMP-1 and a blank control were added. Only TIMP-1 :MMP-9 complexes and free MMP-9 were bound by the capture polyclonal anti-MMP-9 antibody. MAC19 was then added for antigen detection. Neither TIMP- 1 :MMP-9 complex nor free MMP-9 were detected by MAC19, defining the specificity of this antibody for free TIMP-1.
• FIG 11 A plate was coated with the polyclonal anti-MMP-9 antibody. Different concentrations of TIMP-1 :MMP-9 complex, free MMP-9, free TIMP-1 and a blank control were added. Only TIMP-1 :MMP-9 complexes and free MMP-9 were bound by the capture polyclonal anti-MMP-9 antibody. MAC15 was then added for antigen detection. Only TIMP- 1 :MMP-9 complex bound by the capture polyclonal anti-MMP-9 antibody was detected by MAC15. Free MMP-9 was not detected by MAC15.
• Figure 12 Recovery of signal in the free TIMP-1 assay from standard TIMP-1 added in increasing concentration to assay dilution buffer ( D - D ), a dilution of EDTA plasma pool ( ⁇ - ⁇ ), a dilution of citrate plasma pool (V-V), and a dilution of heparin plasma pool (O-O).
• D - D assay dilution buffer
• ⁇ - ⁇ dilution of EDTA plasma pool
• V-V citrate plasma pool
• O-O heparin plasma pool
• Figure 16 Box plot showing total TIMP-1 concentrations in plasma from healthy blood donors, from patients with Crohn's Disease, from patients with ulcerative colitis and from pa- tients with colorectal cancer. Medians, 10th, 25th, 75th and 90th centiles are shown.
• Figure 20 Percentiles plot for the level of total TIMP-1 ( ⁇ g/L) measured by ELISA in 19 EDTA plasma samples from female breast cancer patients (O) and 87 healthy blood do- nors ( ⁇ ).
• Blood samples were initially obtained from 94 apparently healthy volunteer blood donors, comprising 51 males aged 19 to 59 years (median: 41 years) and 43 females aged 20 to 10 64 years (median: 36 years). In a subsequent collection, 100 donor samples were obtained, comprising 56 males aged 19 to 59 years (median 42: years) and 44 females aged 20 to 60 years (median: 36.5 years). Informed consent was obtained from all donors, and permission was obtained from the local Ethical Committees.
• Peripheral blood was drawn with minimal stasis (if necessary a maximum of 2 min stasis with a tourniquet at maximum +2 kPa was acceptable) into pre-chilled citrate, EDTA, or heparin collection tubes (Becton-Dickinson, Mountain View, CA), mixed 5 times by inversion, and immediately chilled on ice.
• the plasma and blood cells were separated by centrifugation at 4°C at 1 ,200 x g for 30 min, and stored frozen at -80°C prior to assay.
• Plasma pools were made with freshly collected samples from at least ten donors, aliquoted and stored frozen at -80°C. For analysis, the samples were quickly thawed in a 37°C water bath at and then placed on ice until needed.
• a sensitive and specific sandwich ELISA was prepared, using TIMP-1 antibodies developed at the Strangeways Laboratories (Hembry et al, 1985).
• a sheep polyclonal anti-TIMP-1 antiserum (Hembry et al, 1985; Murphy et al, 1991) was used for antigen capture, and a 30 murine monoclonal anti-TIMP-1 lgG1 (MAC-15) (Cooksley et al, 1990) for antigen detection.
• a rabbit anti-mouse immunoglobulin/alkaline phosphatase conjugate (Catalog number D0314, Dako, Glostrup, Denmark) was the secondary detection reagent.
• the latter conjugate was supplied preabsorbed against human IgG, thus eliminating cross-reactivity with IgG in the plasma samples.
• the monoclonal detection antibody MAC-15 recog- nises both free TIMP-1 and TIMP-1 in complex with MMP's (Cooksley et al, 1990)
• the total TIMP-1 content captured by the sheep polyclonal anti-TIMP-1 antiserum was quan- titated by the ELISA.
• 96-well microtiter plates (Maxisorp, Nunc, Roskilde, Denmark) were coated for 1 h at 37°C with 100 ⁇ L/well of polyclonal sheep anti-TIMP-1 (4 mg/L) in 0.1 mol/L carbonate buffer, pH 9.5. The wells were then rinsed twice with 200 ⁇ L/well of SuperBlockJ solution (Pierce Chemicals, Rockford, IL) diluted 1 :1 with phosphate-buffered saline (PBS). The microtiter plates were stored for up to 14 days at -20°C. On the day of analysis, the plates were thawed at room temperature and washed 5 times in PBS containing 1 g/L Tween.
• a series of purified, recombinant human TIMP-1 standards were used to calibrate each plate.
• Standards were prepared by serially diluting a stock solution of purified TIMP-1.
• Standard concentrations were 10, 5, 2.5, 1.25, 0.625, 0.313 and 0.156 ⁇ g/L. Included on each plate was a blank containing only sample dilution buffer, and 2 controls made from a 1 :100 dilution of a citrate plasma pool. One control was added as the first sample on the plate and the second control was added as the last.
• All plasma samples were diluted 1 :100 in sample buffer consisting of 50 mol/L phosphate, pH 7.2, 0.1 mol/L NaCI, 10 g/L bovine serum albumin (Fraction V, Boehhnger-Mannheim, Penzberg, Germany), and 1 g/L Tween 20.
• sample buffer consisting of 50 mol/L phosphate, pH 7.2, 0.1 mol/L NaCI, 10 g/L bovine serum albumin (Fraction V, Boehhnger-Mannheim, Penzberg, Germany), and 1 g/L Tween 20.
• a total of 100 ⁇ L/well of each standard, blank, control, and patient sample was incubated on the plate for 1 h at 30°C. All standards, blanks, controls, and samples were run in triplicate on each plate for every assay.
• the wells were washed 5 times, then treated for 1 h at 30°C with 100 ⁇ L/well of purified MAC-15 monoclonal antibody (0.5 mg/L) in sample dilution buffer. After another 5 washes the wells were incubated for 1 h at 30°C with 100 ⁇ L/well of rabbit anti-mouse immunoglobu- lins(lg)/alkaline phosphatase conjugate diluted 1 :2000 in sample dilution buffer. Following 5 washes with washing solution and 3 washes with distilled water, 100 ⁇ L of freshly made p-nitrophenyl phosphate (Sigma, St.
• TIMP-1 signal was measured following addition to 1 :100 dilutions of citrate, EDTA or heparin plasma pools. Purified TIMP-1 was added to plasma pools to give final concentrations in the range of 0 to 10 ⁇ g/L. The recovery in each case was calculated from the slope of the line representing TIMP-1 signal as a function of concentration, where 100% recovery was defined as the slope obtained when TIMP-1 was diluted in sample dilution buffer.
• Proteins were transferred electrophoretically from the gel onto a polyvinylidene difluoride (PVDF) membrane (Millipore).
• PVDF polyvinylidene difluoride
• the membrane was incubated for 1 h at room temperature with 1% skim milk powder in TBS. Following washing, the mem- brane was incubated for 1 h at room temperature with 20 ml of MAC-15 (5 mg/L). The membrane was then washed and incubated for an additional hour at room temperature with 20 ml of rabbit anti-mouse Ig/alkaline phosphatase conjugate diluted 1 :1000. Finally the membrane was washed and color developed by the addition of a phosphate substrate solution (NBT/BCIP).
• NBT/BCIP phosphate substrate solution
• the limit of detection for the assay defined as the concentration of TIMP-1 corresponding to a signal 3 SD above the mean for the TIMP-1 blank, was 0.089 ⁇ g/L. This value was 13% of the mean of the measured concentrations of TIMP-1 in healthy citrate plasma samples .
• the intra-assay coefficient of variation (CV) for 16 replicates of a control citrate plasma pool was 5.3%, and the inter-assay CV for 29 successive assays of the plasma pool (run on different days) was 6.2%.
• This plasma pool had a TIMP-1 concentration of 57.8 ⁇ g/L, corresponding to the 22nd centile of the normal individuals.
• MMP:TIMP complexes may be unstable in SDS-PAGE (Wilhelm et al, 1989; Stetler-Stevenson et al, 1989; Moll et al, 1990), even under non-reducing conditions (Moutsiakis et al, 1992).
• citrate and EDTA plasma samples taken simultaneously from 100 healthy donors were available for this study. These samples were not specifically collected as platelet-poor plasma. However, a small, representative number of samples, prepared as platelet-poor plasma, did not differ significantly in total TIMP-1 values.
• the percentile plots for total TIMP-1 levels in these samples are shown in Figure 5a. The values in each set approximated a normal distribution.
• Citrate plasma TIMP-1 levels ranged between 55.0 and 90.3 ⁇ g/L (10th to 90th percentile) with a mean of 69.2 ⁇ 13.1 ⁇ g/L.
• EDTA plasma TIMP-1 levels ranged from 58.0 to 91.8 ⁇ g/L with a mean of 73.5 ⁇ 14.2 ⁇ g/L.
• TIMP-1 levels were in close proximity to the median levels (Table 1).
• a paired means comparison showed that the level of TIMP-1 in citrate plasma was significantly lower by 4.34 ⁇ g/L (95% Cl 2.34-6.33; (p ⁇ 0.0001) than the EDTA plasma level from the same individual.
• EDTA plasma tubes contained dry anticoagulant material
• citrate plasma tubes contained a small amount of liquid citrate buffer which gave a small and variable systematic dilution error (x 9/10).
• the level of TIMP-1 in citrate plasma correlated with that in EDTA plasma from the same individuals.
• FIG. 6 shows the percentile plots for TIMP-1 levels measured in these two independent groups.
• the reference range for TIMP-1 levels in citrate plasma from the first collection was 53.3 to 77.7 ⁇ g/L (10th to 90th percentile) with a mean of 65.4 ⁇ 10.1 ⁇ g/L which was indistinguishable from the median (Table 1). and approximating a normal distribution.
• the mean TIMP-1 level for the second collection was 69.2+13.1 ⁇ g/L (reference range 55.0 to 90.3 ⁇ g/L).
• the mean TIMP-1 level for all 194 citrate plasma samples was 67.3 ⁇ 11.8 ⁇ g/L, close to the median of 66.1 ⁇ g/L, with levels again approximating a normal distribution (reference range 54.0 to 82.7 ⁇ g/L).
• the assay described above enables accurate determination of total TIMP-1 in human plasma samples.
• Kinetic rate assays of the bound antigen were easily accomplished, permitting automated fitting of rate curves, which has proven considerably more reliable than single end-point measurements.
• the use of a rapid blocking agent and a dilution buffer with high buffering capacity also contributed to reproducible assays. Incorporating all these elements in the final assay fulfilled the requirements of sensitivity, specificity, stability, and good recovery of an internal standard.
• TIMP-1 levels in healthy individuals both EDTA and citrate
• Mean TIMP-1 levels were approx. 10% higher in males than in females for both EDTA and citrate plasma.
• One explanation for this is a higher release rate of TIMP-1 into blood from activated platelets, reflecting a tendency towards higher incidence of thrombo- embolic disease in the male population.
• males and females were considered separately, there was a weak correlation between TIMP-1 and age as seen for the whole population (see above).
• the following example describes an assay to determine the concentration of TIMP- 1 :MMP-9 complexes in body fluids.
• the assay is used with plasma samples of healthy blood donors in order to establish normal ranges of this complex (Holten Andersen et al., 1999).
• a sensitive and specific sandwich ELISA was prepared using the above-described TIMP-1 antibody, MAC-15, and a rabbit MMP-9 polyclonal antibody developed in the Hematologi- cal Department, Rigshospitalet, Denmark (Kjeldsen et al, 1992).
• the MMP-9 antibody was used for antigen capture and MAC-15was used for antigen detection.
• a rabbit anti-mouse- Ig/alkaline phosphatase conjugate (Dako, Glostrup, Denmark) enabled a kinetic rate assay (Figure 8). The latter conjugate was supplied preabsorbed against human IgG, thus eliminating cross-reactivity with IgG in the plasma samples.
• the MMP-9 antibody captured both free MMP-9 and MMP-9 complexed with TIMP-1 , while MAC-15 only recog- nised TIMP-1. Therefore only TIMP-1 :MMP-9 complexes were quantitated by this reagent pair.
• a protease inhibitor ie. Galardin, Batimastat, Marimastat
• Galardin, Batimastat, Marimastat a protease inhibitor
• the TIMP-1 :MMP-9 assay was prepared and validated by a method similar to that described above for the total TIMP-1 assay.
• the TIMP-1 :MMP-9 standard was prepared by incubating equimolar amounts of purified recombinant TIMP-1 and MMP-9 (activated by adding APMA) in PBS for 1 hour at 37 degrees Celsius.
• 96-well micotiter plates were coated overnight at 4°C with 100 ⁇ L/well of rabbit polyclonal anti-MMP-9 antiserum in 0.1 mol/L carbonate buffer, pH 9.5. Prior to use, as- say wells were rinsed twice with 200 ⁇ L/well of SuperBlock solution diluted 1 : 1 with phosphate-buffered saline (PBS), and then washed 5 times in PBS containing 1 g/L Tween 20. Wells were then incubated for 1 h at 30°C with 100 ⁇ L/well of plasma diluted in sample buffer A series of purified TIMP-1 :MMP-9 standards were used to calibrate each plate.
• PBS phosphate-buffered saline
• Standards were prepared by serially diluting a stock solution of purified TIMP-1 :MMP-9 complex. Included on each plate was a blank containing only sample dilution buffer, and 2 controls made from a citrate plasma pool. One control plasma pool was added as the first sample on the plate and the second control was added as the last. All standards, blanks, controls, and samples were run in triplicate on each plate for every assay. After sample incubation and TIMP-1 :MMP-9 complex binding, the wells were washed 5 times, followed by treatment for 1 h at 30°C with 100 ⁇ L/well of MAC-15 in sample dilution buffer.
• TIMP-1 :MMP-9 complex Specific recovery was determined by addition of TIMP-1 :MMP-9 complex to a series of citrate, EDTA or heparin plasma pools. The recovery in each case was calculated from the slope of the line representing TIMP-1 :MMP-9 complex signal as a function of concentration, where 100% recovery was defined as the slope obtained when TIMP-1 :MMP-9 complex was diluted in the sample dilution buffer.
• TIMP-1 levels in body fluids are applied to plasma samples of healthy blood donors in order to establish normal ranges of free TIMP-1.
• a sensitive and specific sandwich immunoassay was prepared, using a TIMP-1 monoclonal lgG1 antibody (MAC-19) developed at the Strangeways Laboratories, England (Cooksley et al, 1990) and a sheep polyclonal anti-TIMP-1 antibody.
• the sheep polyclonal anti-TIMP-1 antibody was used for antigen capture and the murine monoclonal MAC-19 was used for antigen detection.
• a rabbit anti-mouse-lg/alkaline phosphatase conjugate was the secondary detection reagent ( Figure 9). The latter conjugate was supplied preab- sorbed against human IgG, thus eliminating cross-reactivity with IgG in the plasma samples.
• the MAC-19 monoclonal antibody is completely specific for free TIMP-1 , which therefore is the only form quantitated in this assay.
• the rabbit polyclonal anti-MMP-9 antibody described in Example 2 was used for antigen capture and the mouse monoclonal antibody MAC19 for antigen detection.
• a rabbit anti- mouse-lg/alkaline phosphatase conjugate was used as the secondary labelled reagent.
• Standard TIMP-1 :MMP-9 complex, free MMP-9, free TIMP-1 , and a blank control were assayed.
• Figure 10 shows that TIMP-1 :MMP-9 complexes bound by the polyclonal anti- MMP-9 antibody are not detected by MAC19.
• An equivalent experiment was performed, where MAC19 was substituted with MAC15.
• Figure 11 shows the results of this experi- ment. It is seen that MAC15 detects TIMP-1 :MMP-9 complex bound by the polyclonal anti-MMP-9 antibody.
• a protease inhibitor ie. Galardin, Batimastat, Marimastat
• Galardin, Batimastat, Marimastat a protease inhibitor
• 96-well micortiter plates were coated for 1 h at 37°C with 100 ⁇ L/well of polyclonal sheep anti-TIMP-1 (4 mg/L) in 0.1 mol/L carbonate buffer, pH 9.5. The assay wells were then rinsed twice with 200 ⁇ L/well of SuperBlock solution diluted 1 :1 with phosphate-buffered saline (PBS). The microtiter plates were stored for up to 14 days at -20°C. On the day of use, the plates were thawed at room temperature and washed 5 times in PBS containing 1 g/L Tween 20.
• PBS phosphate-buffered saline
• each plate was a blank containing only sample dilution buffer, and 2 controls made from a citrate plasma pool diluted 1 :25. One control plasma pool was added as the first sample on the plate and the second control was added as the last. All standards, blanks, controls, and samples were run in triplicate on each plate for every assay. After TIMP-1 binding, the wells were washed 5 times, then treated for 1 h at 30°C with 100 ⁇ L/well of the purified murine monoclonal anti-TIMP MAC-19 (0.5 mg/L) in sample dilution buffer.
• Free TIMP-1 was measurable in all plasma samples.
• the median free TIMP-1 concentration was 70.9 ⁇ g/L (range: 32.3-169.7 ⁇ g/L).
• This assay directly measures plasma free TIMP-1 levels.
• free TIMP-1 levels with total TIMP-1 levels (the latter measured with assay described in Example 1) in the 108 healthy blood donors, a correlation coefficien of 0.46 (Rho, Spearman Rank, p ⁇ 0.0001) was obtained.
• TIMP-1 levels in plasma from 591 colorectal cancer patients (338 colon and 253 rectal) and in plasma from 108 age and gender matched healthy individuals were measured with the TIMP-1 assay described in Example 1.
• the TIMP-1 values were analyzed and compared using standard biostatistical parameters.
• the median age of the patients was 69 years (range 33-90 years) with 237 females and 354 males represented in the patient cohort.
• a second patient cohort was collected prospectively. This cohort consisted of 21 rectal cancer and 43 colon cancer patients. There were 11 patients with Dukes ' stage A, 27 with Dukes ' stage B, 14 with Dukes ' stage C, and 13 with Dukes ' stage D disease.
• TIMP-1 ELISA TIMP-1 levels were measured in EDTA plasma samples using the assay described in Example 1.
• TIMP-1 levels were determined in all patient and healthy donor plasma samples. Every plasma sample had measurable levels of TIMP-1 , with a median total TIMP-1 value for the 591 colorectal cancer patients of 141.1 ⁇ g/L (range 53.7 - 788.7 ⁇ g/L). When stratified into colon and rectal cancer, the median values were 158.6 ⁇ g/L (range: 53.7-788.7 ⁇ g/L) for colon and 126.3 (range: 64.1-640.1 ⁇ g/L) for rectal cancer.
• the median total TIMP-1 value for the 64 colorectal cancer patients was 138.2 ⁇ g/L (range: 80.7-790.6 ⁇ g/L). Stratifying the patients into colon and rectal cancer, the median, total TIMP-1 values were 152.2 ⁇ g/L (range: 80.7-626.2 ⁇ g/L) for colon and 133.6 (range: 84.3-790.6) for rectal cancer. There was a highly statistical difference in the total plasma TIMP-1 values between the colon and rectal cancer patients each compared with the healthy blood donors.
• ROC Receiver Operating Characteristics
• ROC curves were again constructed to confirm the diagnostic value of TIMP-1. As seen in Figure 15, the curve was again initially steep, indicat- ing a high sensitivity and specificity of total TIMP-1 as a marker for colorectal cancer.
• total TIMP-1 measurements in plasma can be used as a screening procedure to aid in identifying patients with a high risk of having colorectal cancer.
• total TIMP-1 was as effective in identifying patients with early cancer (Duke's stage A+B) as identifying patients with more advanced disease.
• total TIMP-1 was even more effective in identifying patients with early stage, right-sided colon cancer, a diagnosis that is difficult with conventional diagnostic procedures.
• Right-sided colon cancer cannot be visualized by flexible sigmoidoscopy, a standard colon cancer screening methodology. It has a more insidious onset than do left-sided lesions, and clinical symptoms develop only in late stage disease. Early diagnosis of right sided colon cancer has the potential to reduce the mortality of this disease.
• Total TIMP-1 levels were measured in the EDTA plasma samples using the sandwich assay described in Example 1.
• the measured total TIMP-1 values are shown in Table 2.
• TIMP-1 in plasma from 591 colorectal cancer patients (338 colon and 253 rectal) and in plasma from 108 age and gender matched healthy individuals was measured using the TIMP-1 assay described in Example 1.
• CEA was measured in the corre- sponding patient and donor serum samples using a commercially available, chemilumi- nescent CEA EIA kit (Immulite CEA, DPC ® , Los Angeles, California, USA). The TIMP-1 and CEA values from healthy donors and cancer patients were combined by logistic regression analysis and ROC curves were generated.
• CEA and TIMP-1 could be useful as a screening procedure to identify patients with a high risk of having colorectal cancer.
• this combination was efficient in identifying patients with early stage cancer (Duke's stage A+B).
• this combination was highly effective in identifying patients with early stage, right-sided colon cancer.
• TIMP-1 levels in plasma from 64 colorectal cancer patients (43 colon and 21 rectal) and in plasma from 108 age matched, healthy individuals were measured using the TIMP- 1 assay described in Example 3.
• the free TIMP-1 values were analysed and compared using standard biostatistical parameters.
• Figure 18 shows the ROC curves generated from the plasma measurements of free TIMP-1.
• the AUC is 0.61 when determining the diagnostic performance of free TIMP-1.
• TIMP-1 :MMP-9 complex levels in plasma from colorectal cancer patients and in plasma from age and gender matched healthy individuals can be measured using the TIMP- 1 :MMP-9 assay described in Example 2.
• TIMP-1 :MMP-9 complex values from healthy donors and cancer patients can be compared and the diagnostic value determined.
• the diag- nostic value of ratios or fractions can be calculated.
• other molecules e.g. serum CEA can be added to these calculations to generate mathematical algorithms to increase the overall diagnostic value.
• Example 9 Diagnostic value of the combination of plasma total TIMP-1 and plasma free TIMP-1 in patients with colorectal cancer
• TIMP-1 levels in plasma from 64 colorectal cancer patients and in plasma from 108 age and gender matched healthy individuals were measured with the TIMP-1 assay de- scribed in Example 1.
• plasma free TIMP-1 levels were measured in the same individuals as described above.
• the total and the free TIMP-1 values were analyzed and compared using logistic regression analysis.
• Blood samples (5 mL) were collected preoperatively from all patients on the day of their surgery. To ensure valid TIMP-1 measurements, peripheral blood was drawn with minimal stasis and collected in EDTA anticoagulant tubes (Becton-Dickinson, Mountain View, CA) in accordance with a previously described protocol (Example 1 ).
• EDTA anticoagulant tubes Becton-Dickinson, Mountain View, CA
• TIMP-1 levels were measured in EDTA plasma samples using the assays described in Example 1 and Example 3.
• ROC curves were constructed for each of these TIMP-1 forms.
• the total TIMP-1 values obtained confirm the diagnostic value of total TIMP-1 measure- ments in patients with colorectal cancer .
• the curve was again initially steep, indicating a high sensitivity and specificity of total TIMP-1 as a marker for colorectal cancer.
• the ROC curve for free TIMP-1 was discussed in Example 7.
• TIMP-1 total and free TIMP-1 , total concentration of complexes (total TIMP-1 - free TIMP-1), and/or the concentration of TIMP-1 :MMP-9, might be extremely useful in the management, and especially the differential diagnosis of patients with non-malignant diseases and patients with cancer.
• TIMP-1 levels were measured in all EDTA plasma samples using the assay described in Example 1.
• Total TIMP-1 was measured in EDTA plasma samples from 19 breast cancer patients with stage IV disease. These levels were compared with total TIMP-1 levels in 87 healthy female donors.
• the mean, total TIMP-1 level measured in the 19 breast cancer patients was 292 ⁇ 331 ⁇ g/L (median: 236 ⁇ g/L), compared with a mean, total TIMP-1 level of 63.5+10.5 ⁇ g/L (median: 62.0 ⁇ g/L) in 87 healthy female donors.
• a Wald-Wolfowitz runs test indicated a highly significant difference (p ⁇ 0.0001) between patient total TIMP-1 levels and those of healthy donors.
• Figure 20 shows a percentile plot of total TIMP-1 levels in from the 19 breast cancer patients and the TIMP-1 levels found in plasma from the 87 healthy female donors.
• TIMP-2 levels were measured with an in-house TIMP-2 assay in plasma from 64 colorec- tal cancer patients ( 43 colon and 21 rectal) and in plasma from 108 age matched healthy individuals. The measured TIMP-2 values from healthy donors and cancer patients were compared.
• TIMP-2 was measurable in all samples. No significant differences in TIMP-2 levels were found between healthy blood donors and colorectal cancer patients.
• Tissue inhibitor of metalloproteinase Tissue inhibitor of metalloproteinase (TIMP-2).
• Tissue inhibitor of metalloproteinase Tissue inhibitor of metalloproteinase (TIMP-2).
• Tissue inhibitor of metalloproteinase Tissue inhibitor of metalloproteinase (TIMP-2).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Urology & Nephrology (AREA)
• Molecular Biology (AREA)
• Biomedical Technology (AREA)
• Chemical & Material Sciences (AREA)
• Hematology (AREA)
• Cell Biology (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Hospice & Palliative Care (AREA)
• Biotechnology (AREA)
• Food Science & Technology (AREA)
• Oncology (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Biochemistry (AREA)
• Microbiology (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (2)

Family

ID=8093987

Family Applications (1)

Country Status (11)

Cited By (10)

Families Citing this family (19)

Citations (2)

Family Cites Families (37)

• 2000
  • 2000-04-10 EP EP00915142A patent/EP1171771B1/en not_active Expired - Lifetime
  • 2000-04-10 JP JP2000611082A patent/JP4638608B2/ja not_active Expired - Fee Related
  • 2000-04-10 CA CA002366682A patent/CA2366682C/en not_active Expired - Fee Related
  • 2000-04-10 US US09/546,573 patent/US7108983B1/en not_active Expired - Fee Related
  • 2000-04-10 AU AU36556/00A patent/AU771309B2/en not_active Ceased
  • 2000-04-10 ES ES00915142T patent/ES2244417T3/es not_active Expired - Lifetime
  • 2000-04-10 NZ NZ515311A patent/NZ515311A/xx not_active IP Right Cessation
  • 2000-04-10 DE DE60021068T patent/DE60021068T2/de not_active Expired - Lifetime
  • 2000-04-10 CA CA002652131A patent/CA2652131A1/en not_active Abandoned
  • 2000-04-10 WO PCT/DK2000/000170 patent/WO2000062070A2/en active IP Right Grant
  • 2000-04-10 EP EP05013914A patent/EP1619206A3/en not_active Withdrawn
  • 2000-04-10 AT AT00915142T patent/ATE298890T1/de not_active IP Right Cessation
• 2001
  • 2001-10-05 NO NO20014869A patent/NO329725B1/no not_active IP Right Cessation
• 2006
  • 2006-06-09 US US11/449,869 patent/US7807379B2/en not_active Expired - Fee Related
• 2008
  • 2008-04-11 US US12/101,661 patent/US20080261246A1/en not_active Abandoned
  • 2008-08-07 US US12/187,939 patent/US20090035794A1/en not_active Abandoned
• 2010
  • 2010-07-05 JP JP2010152840A patent/JP2010266455A/ja not_active Ceased
  • 2010-08-30 US US12/871,735 patent/US20110060529A1/en not_active Abandoned
• 2011
  • 2011-08-04 US US13/198,519 patent/US20110294148A1/en not_active Abandoned

Patent Citations (2)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events